Establishment and characterization of a new, factor-independent acute myeloid leukemia line designated Ei501

Leukemia
E WeidmannL Bergmann

Abstract

We established a factor-independent acute myeloid leukemia cell line, designated Ei501. The line has been growing in RPMI 1640 media for 18 months and can be maintained without addition of growth factors. Ei501 is positive for myeloperoxidase and negative for esterase and PAS. Cytogenetic analysis revealed the FAB M3 associated t(15;17) translocation and a translocation of the chromosomes 7 and 8: 46 XX, -7, +t(7;8)(q32;q13), t(15;17)(q22;q12). This karyotype was confirmed by fluorescence in situ hybridization. Ei501 cells express AML-associated surface markers such as CD13, CD33 and CD38. Although 42% of the patient's blast cells were CD34-positive, the line lacks surface expression of CD34. Furthermore the line has a number of characteristics which are detectable in blasts from AML patients, such as surface adhesion molecules, cytokines such as TGF-beta, cytokine receptors such as the IL-2 receptor beta and gamma chains or the IL-4 receptor and the genes for the transcription factor wt-1 (Wilms' tumor gene) and for the proto-oncogene bcl-2, both shown to be present in the majority of patients with AML. Additionally the line can be used as target in cytotoxicity assays using IL-2 activated cytotoxic lymphocytes as effector cel...Continue Reading

Citations

May 25, 2001·International Journal of Hematology·H Sugiyama
Nov 15, 2002·International Journal of Hematology·Stanley R RiddellE H Warren
Nov 8, 2005·Cancer Chemotherapy and Pharmacology·Michael F Clarke
Jan 1, 2014·Pathology Oncology Research : POR·Zsófia UjjLászló Rejtő
Feb 24, 2006·Archives of Pharmacal Research·Songyot AnuchapreedaPrasit Chanarat
Jan 29, 2011·Annals of Hematology·Alexandar TzankovUrsula Günthert
Feb 2, 2006·Cancer Immunology, Immunotherapy : CII·Lucas ChanFarzin Farzaneh
Dec 17, 2008·PloS One·Marta Gómez-NuñezDavid A Scheinberg
May 29, 2002·Oncogene·Utz KrugH Phillip Koeffler
May 29, 2002·Oncogene·Shinichi KitadaJohn C Reed
Oct 19, 2001·Oncogene·J DuysterS W Morris

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.